Safety and Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

A Study of the Safety and IOP-Lowering Efficacy of Anecortave Acetate in Patients With Open-Angle Glaucoma

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00451152

Enrollment

Registered

2007-03-23

Start date

2007-03-31

Completion date

2009-07-31

Last updated

2012-11-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Open-angle Glaucoma

Keywords

glaucoma

Brief summary

The purpose of this study was to evaluate the safety and intraocular pressure (IOP)-lowering efficacy of anecortave acetate for treatment of elevated IOP in patients with open-angle glaucoma.

Interventions

DRUGAnecortave Acetate Sterile Suspension, 30 mg/mL

Administered by anterior juxtascleral depot (AJD) in study eye, either 0.25 mL or 0.5 mL. One injection, 24 months.

OTHERAnecortave Acetate Vehicle

Administered by anterior juxtascleral depot (AJD) in study eye, 0.5 mL. One injection, 24 months.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Diagnosis of open-angle glaucoma; * Other protocol-defined inclusion criteria may apply.

Exclusion criteria

* Pseudoexfoliation; * Pigment dispersion component; * Other protocol-defined

Design outcomes

Primary

Measure	Time frame
Mean Intraocular Pressure (IOP)	3 months

Secondary

Measure	Time frame
Percent Treatment Failures	3 months

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026